Latest developments in new drug development for schizophrenia in May 2018 June 19, 2018 Source: WuXi PharmaTech Schizophrenia is a mental disorder characterized by abnormal social behavior and ignorance of reality. People with schizophrenia may have hallucinations (mostly auditory hallucinations), delusions (often singular or persecuted), confusion of thinking and speech. People with schizophrenia often have additional mental health problems such as anxiety, depression or medication use disorders. Symptoms usually appear gradually, starting from puberty and lasting for a long time. Schizophrenia affects approximately 24 million people worldwide. According to data from the World Health Organization in 2000, the global prevalence of schizophrenia is close to 1%, and about 1.5 out of every 10,000 people. The incidence of men is 1.4 times higher than that of women, and usually men appear earlier – the peak age of onset is 25 for men and 27 for women. Image source: 123RF Causes of schizophrenia include environmental and genetic factors. Environmental factors include growing up in cities, using cannabis during adolescence, certain infections, parental age and malnutrition during pregnancy. Genetic factors include a variety of common and rare genetic mutations. Diagnosis is based on observed behavior, patient reported experience, and reports from others familiar with the patient. As of 2013, there is no objective test. Symptoms of schizophrenia are classified as positive and negative. Positive symptoms are symptoms that healthy people usually do not experience, and may include delusions, hallucinations, thought disorders, and movement disorders. Positive symptoms usually respond well to drugs. Negative symptoms are associated with interruptions in normal mood and behavior, and poor response to medication, often including lack of mood, lack of speech, lack of pleasure, lack of desire, and lack of motivation. The main treatment for schizophrenia is antipsychotic medication, usually combined with psychotherapy and social support. One of the first-line treatments is antipsychotics, which can reduce the positive symptoms of psychosis within 7 to 14 days. However, antipsychotics do not significantly improve negative symptoms and cognitive dysfunction. Amisulpride, olanzapine, risperidone, and clozapine are common schizophrenia drugs. " Progress in clinical research and development of new drugs for schizophrenia As of May 31, 2018, there were 108 clinical trials of new drugs in the field of schizophrenia, with Phase 2 predominating. 108 studies included 28 trials in Phase 1, including 27 small molecule drugs and 1 biologic drug; 47 trials in Phase 2, all of which were small molecule drugs; and 33 trials in Phase 3, All are small molecule drugs (Note: Some drugs may be tested at the same time). The clinical trials of new drugs for schizophrenia are concentrated in the United States. According to the location of the research institutions of clinical trials, the top 5 countries or regions are: 73 trials in the United States, 13 in Bulgaria, 13 in Russia, 12 in Serbia, 12 in Ukraine. Item (Note: There may be a multicenter clinical trial). The world's leading companies investigating new drugs for schizophrenia are: Alkermes (5 items), ACADIA (5 items), Otsuka (4 items), Sunovion (4 items), SyneuRx (3 items), Lundbeck (3 items), Boehringer Ingelheim ( 3 items), Takeda (2 items), Brian Miller (2 items), Iris Sommer (2 items), Rovi (2 items), Sumitomo Dainippon Pharma Co., Ltd. (2 items), Braeburn (2 items), Marinus (2 items), Millennium (1 item), Roche (1 item). New clinical trial of new drugs for schizophrenia in 2018 In 2018, 11 new clinical trials of schizophrenia were added. One 1/2-stage trial enrolled an average of 70 subjects, two of the first-phase trials enrolled an average of 37 subjects, two 2/3 trials enrolled an average of 153 subjects, and three of the two trials averaged Of the 57 subjects, 3 of the 3 trials enrolled an average of 434 subjects. We expect these clinical trials to go well and achieve positive results as soon as possible, bringing hope for treatment to patients. Reflective Sheeting,3M Reflective Sheeting,Best Reflective Tape,Colored Reflective Tape Kunshan Jieyudeng Intelligent Technology Co., Ltd. , https://www.jerrytape.com
